Hematology (all articles)
Editorial: Prophylactic anticoagulation for patients in hospital with covid-19
23 Feb, 2021 | 01:59h | UTCProphylactic anticoagulation for patients in hospital with covid-19 – The BMJ
Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
COVID‐19 convalescent plasma: Interim recommendations from the AABB
19 Feb, 2021 | 02:56h | UTCCOVID‐19 convalescent plasma: interim recommendations from the AABB – Transfusion
News release: AABB panel issues interim recommendations for Covid-19 convalescent plasma use
Defining the optimal total number of chemotherapy courses in younger patients with Acute Myeloid Leukemia: A comparison of 3 vs. 4 courses
19 Feb, 2021 | 02:06h | UTCDefining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Optimal Number of Treatment Courses Explored in Younger Patients with AML – CancerNetwork
Commentary on Twitter
What is the optimal number of chemotherapy courses in younger patients with acute myeloid leukemia (AML)? This study evaluates 3 vs 4 courses https://t.co/peC7Xo3BbX #leusm #JCO pic.twitter.com/OGChNkYS0X
— Journal of Clinical Oncology (@JCO_ASCO) January 6, 2021
M-A: The effect of convalescent plasma therapy on COVID-19 patient mortality
18 Feb, 2021 | 03:07h | UTCRelated study (not published yet) with conflicting results: RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19 (news release and commentary)
Short review: Acute CV complications of hematopoietic stem cell transplantation
18 Feb, 2021 | 02:40h | UTCAcute CV Complications of Hematopoietic Stem Cell Transplantation – American College of Cardiology
COVID-19: A Hematologist’s Perspective
17 Feb, 2021 | 01:35h | UTCCoronavirus Disease 2019 (COVID-19): A Haematologist’s Perspective – Acta Haematologica
Editorial: A Haematologist’s Guide to Coronavirus Disease 2019: Encyclopaedia or Doorstop?
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
15 Feb, 2021 | 00:49h | UTC
Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
15 Feb, 2021 | 01:18h | UTCCommentaries: Preventive blood thinning drugs could reduce COVID hospital deaths – London School of Hygiene & Tropical Medicine AND Preventive blood thinning drugs linked to reduced risk of death in COVID-19 patients – The BMJ AND Expert reaction to a study looking at prophylactic anticoagulants as a treatment for hospitalised patients with COVID-19 – Science Media Centre AND
Commentary on Twitter
Blood thinning drugs are now linked to a reduced risk of death for COVID19 patients. Those given preventive blood thinners (prophylactic anticoagulants) within 24 hours of hospital admission for Covid were less likely to die. New report in the BMJ https://t.co/KQqQ3Zoj8B pic.twitter.com/6wJj8mEucw
— delthia ricks 🔬 (@DelthiaRicks) February 12, 2021
RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy
10 Feb, 2021 | 01:39h | UTCEffect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Restrictive vs. Liberal Blood Transfusion Strategy for MI and Anemia – American College of Cardiology
Commentary on Twitter
Effect of Restrictive vs Liberal Blood Transfusion Strategy on Adults With Myocardial Infarction and Anemia https://t.co/PUtmUj0haw
— JAMA Cardiology (@JAMACardio) February 9, 2021
RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL
9 Feb, 2021 | 00:39h | UTCCommentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)
Commentary on Twitter
Total body irradiation or chemotherapy conditioning in childhood acute lymphoblastic leukemia (ALL) — outcomes suggest there's still a role for TBI https://t.co/ICTC0iEGN8 #leusm #pedonc #pedcsm #JCO pic.twitter.com/xARMBlSeni
— Journal of Clinical Oncology (@JCO_ASCO) December 26, 2020
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
9 Feb, 2021 | 01:41h | UTCThrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases
Commentary on Twitter
https://twitter.com/JohnRossMD/status/1357992429824081921
Patients with lymphoma receiving B-Cell–depleting therapies may be at greater risk for persistent COVID-19 infection
9 Feb, 2021 | 01:14h | UTCRelated: Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection – The ASCO Post
See also: Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients — Plus: Active chemo treatment may not be a COVID risk factor – MedPage Today (free registration required)
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer
7 Feb, 2021 | 20:45h | UTCCommentary: ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
3 Feb, 2021 | 01:07h | UTCASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – Blood
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
Preliminary study shows sitagliptin may prevent acute Graft-versus-Host Disease
26 Jan, 2021 | 00:35h | UTCDipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Sitagliptin promising addition for preventing acute GVHD – HealthDay
Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis
25 Jan, 2021 | 01:15h | UTCLong-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)
[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients
25 Jan, 2021 | 01:42h | UTC
Cohort study: Recipients of hematopoietic stem-cell transplantation who develop COVID-19 have poor overall survival
21 Jan, 2021 | 01:18h | UTC
Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb
21 Jan, 2021 | 01:10h | UTCSummary: Thrombolysis for treatment of acute deep vein thrombosis – Cochrane Library
Meta-Analysis: Low-intensity warfarin may be an option for patients under 65 years of age with non-valvular atrial fibrillation
21 Jan, 2021 | 00:57h | UTCMeta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation – The American Journal of Cardiology (link to abstract – $ for full-text)
[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors
21 Jan, 2021 | 00:37h | UTCMyelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: a safety meta-analysis of RCTs and a retrospective study of the WHO pharmacovigilance database shows an increased risk of myelodysplastic syndrome and acute myeloid leukaemia in patients treated w/ PARP inhibitors #MDSsm #leusm https://t.co/evYF1ozg6c
— The Lancet Haematology (@TheLancetHaem) December 21, 2020
Randomized trial: Dabigatran non-inferior to standard of care for children with acute venous thromboembolism
21 Jan, 2021 | 00:35h | UTCDabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial – The Lancet Haematology (link to abstract – $ for full-text)
RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19
17 Jan, 2021 | 22:26h | UTCCommentary: Covid: ‘Convalescent plasma no benefit to hospital patients’ – BBC